Vysotskaia V, Kaseniit KE, Bucheit L, Ready K, et al. Clinical utility of hereditary cancer panel testing: Impact of PALB2, ATM, CHEK2, NBN, BRIP1, RAD51C, and RAD51D results on patient management and adherence to provider recommendations. Cancer 2020;126:549-558.
PMID: 31682005